VistaGen Therapeutics
VTGN
24 hedge funds and large institutions have $4.09M invested in VistaGen Therapeutics in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 3 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
73% more capital invested
Capital invested by funds: $2.36M → $4.09M (+$1.73M)
14% more funds holding
Funds holding: 21 → 24 (+3)
0.05% more ownership
Funds ownership: 0.25% → 0.3% (+0.05%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair & Company
Chicago,
Illinois
|
+$1.07M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$79.3K |
| 3 |
VF
Virtu Financial
New York
|
+$45.4K |
| 4 |
LPL Financial
San Diego,
California
|
+$18.6K |
| 5 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
+$16.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$489K |
| 2 |
PVI
Pura Vida Investments
New York
|
-$308K |
| 3 |
FSA
Fort Sheridan Advisors
Highland Park,
Illinois
|
-$11K |
| 4 |
Morgan Stanley
New York
|
-$45 |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
-$22 |
VTGN Hedge Fund Activity: Q3 2019 in Review
24 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q3 2019, worth a combined $4.09M — up 73% from $2.36M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new VTGN positions and 3 closed out — a net gain of 3 holders — while 5 added to existing stakes and 2 trimmed.
The largest buyer was William Blair & Company, opening a new position worth an estimated $1.07M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $489K sold.
- 24 institutional investors held VistaGen Therapeutics (VTGN) as of Q3 2019, up from 21 in Q2 2019.
- Funds reported $4.09M of VistaGen Therapeutics stock for Q3 2019, up 73% quarter-over-quarter.
- 6 funds opened new VistaGen Therapeutics positions in Q3 2019 and 3 closed out, a net change of +3 holders.
- The largest VistaGen Therapeutics buyer in Q3 2019 was William Blair & Company, an estimated $1.07M added.
- The largest VistaGen Therapeutics seller in Q3 2019 was Sphera Funds Management, an estimated $489K sold.
Based on aggregated 13F filings for Q3 2019.